Regulatory Roadmap for Late 2025: What Federal Policy Shifts Mean for Medicaid Plans

Avalere outlines major federal health policy developments expected through the end of 2025, including Medicare Part D formulary changes, drug pricing negotiations, and ongoing PBM scrutiny under the Trump administration. While focused primarily on Medicare, the piece touches on broader regulatory trends around drug pricing and benefit management that affect Medicaid managed care operations and state policy planning. The analysis provides context for understanding how federal pharmaceutical policy changes may influence Medicaid managed care contracting and formulary strategies.

Pharmacy · Managed Care

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere